DEA rescheduling lags FDA approval by 6+ months, creating a hard access bottleneck.

Even after the US drug regulator approves a psychedelic medicine, the DEA must go through its own formal legal process to reclassify the drug — and that process cannot be rushed. This creates a hard stop between 'approved' and 'available.' Communities, especially vulnerable ones, could bear the cost if this step gets skipped or shortcut.

Scheduling is statutory and deliberate. An approval on a 1-2 month track does not compress my rulemaking. Communities pay when we normalize too fast.